2012
Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
De Souza A, Strober B, Merola J, Oliver S, Franks A. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. Journal Of Drugs In Dermatology 2012, 11: 1224-6. PMID: 23134988.Peer-Reviewed Original ResearchConceptsDiscoid lupus erythematosusDiscoid lupusLupus erythematosusCutaneous Lupus Erythematosus Disease AreaFirst open-label studyTh17-mediated immune responsesOpen-label studyChronic inflammatory disordersEffective therapeutic optionDays of treatmentAdverse eventsIL-23Psoriatic arthritisIL-12Clinical efficacyTherapeutic optionsInflammatory disordersTh1 cellsTreatment modalitiesLeukocyte productionImmune responseLabel studyEnzyme inhibitorsApremilastPilot study
2007
The use of therapeutic interchange for biologic therapies.
Flood J, Mihalik C, Fleming R, Strober B, Zucker D, Burgoyne D. The use of therapeutic interchange for biologic therapies. Managed Care 2007, 16: 51-62. PMID: 17285813.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsProton pump inhibitorsBiologic agentsTherapeutic interchangeRheumatoid arthritisBiologic therapyHMG-CoA reductase inhibitorsSerotonin reuptake inhibitorsPopulation-based outcomesHealth care professionalsMode of administrationOverall treatment costsTolerability profileAppropriate therapyReuptake inhibitorsPsoriasis therapyPump inhibitorsDrug classesIndividual patientsCare professionalsNew agentsEnzyme inhibitorsPatientsReductase inhibitorsTherapy